이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

PHAXIAM Therapeutics 관리

관리 기준 확인 1/4

PHAXIAM Therapeutics' CEO는 Thibaut Fayet, Jun2023 에 임명되었습니다 의 임기는 1.08 년입니다. 는 € 10.92K 가치에 해당하는 회사 주식의 0.09% 직접 소유합니다. 10.92K. 경영진과 이사회의 평균 재임 기간은 각각 1.1 년과 11.2 년입니다.

주요 정보

Thibaut Fayet

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	1.1yrs
CEO 소유권	0.09%
경영진 평균 재임 기간	1.1yrs
이사회 평균 재임 기간	11.2yrs

최근 관리 업데이트

Recent updates

CEO

Thibaut Fayet (56 yo)

1.1yrs

테뉴어

Mr. Thibaut du Fayet serves as Chief Executive Officer at PHAXIAM Therapeutics S.A. since June 23, 2023. He served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharm...

리더십 팀

이름	위치	테뉴어	보상	소유권
Eric Soyer	Deputy CEO	8.8yrs	€379.72k	0.010% € 1.3k
Jérôme Bailly	Deputy CEO	4.5yrs	€247.91k	0.0062% € 765.7
Thibaut Fayet	Chief Executive Officer	1.1yrs	데이터 없음	0.090% € 11.1k
Céline Breda	Chief Technology Officer	1.1yrs	데이터 없음	데이터 없음
Cindy Fevre	Chief Scientific Officer	1.5yrs	데이터 없음	데이터 없음
Naomi Eichenbaum	Director Investor Relations	no data	데이터 없음	데이터 없음
Anne-Cécile Fumey	Vice President of Human Resources	8.4yrs	데이터 없음	0.0014% € 174.3
Karine Charton	Chief Business Officer	1.1yrs	데이터 없음	0.00066% € 81.0
Pascal Birman	Chief Medical Officer	1.1yrs	데이터 없음	데이터 없음
Frederique Vieville	Chief Regulatory Officer	1.1yrs	데이터 없음	데이터 없음
Philip Lorenzi	Consultant & Member of Scientific Board	no data	데이터 없음	데이터 없음
Eric Raymond	Consultant & Member of Scientific Board	no data	데이터 없음	데이터 없음

1.1yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: PHXM 의 관리팀은 경험 (평균 재직 기간 1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Philip Lorenzi	Consultant & Member of Scientific Board	14.5yrs	데이터 없음	데이터 없음
Eric Raymond	Consultant & Member of Scientific Board	14.8yrs	데이터 없음	데이터 없음
Bridget Bax	Consultant & Member of Scientific Board	12.5yrs	데이터 없음	데이터 없음
Arthur Frankel	Consultant & Member of Scientific Board	12.5yrs	데이터 없음	데이터 없음
Kurt Gunter	Consultant & Member of Scientific Board	12.5yrs	데이터 없음	데이터 없음
Guy Rigaud	Board Censor	no data	데이터 없음	0.12% € 15.3k
Philippe Archinard	Independent Director	11.2yrs	€66.00k	0.017% € 2.1k
Gil Beyen	Vice Chairman	11.2yrs	€572.43k	0.0080% € 978.0
Hilde Windels	Independent Director	9.8yrs	€51.00k	0.000020% € 2.5
Didier Hoch	Chairman of the Board	1.1yrs	데이터 없음	데이터 없음
Leila Nicolas	Representative Director	1.5yrs	데이터 없음	데이터 없음
Robert Sebbag	Independent Director	1.1yrs	데이터 없음	데이터 없음

11.2yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: PHXM 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.1 년).

PHAXIAM Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

Recent updates

PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus

PHAXIAM Therapeutics Announces Intention to Voluntary Delist ADS from Nasdaq Capital Market

PHAXIAM Therapeutics S.A. to Report Q3, 2024 Results on Nov 13, 2024

PHAXIAM Therapeutics Obtains Authorizations to Launch Its Phase 1 Study in Endocarditis Infections Caused by Staphylococcus Aureus

New major risk - Revenue and earnings growth

PHAXIAM Therapeutics Announces High Coverage Performance of Its Two Anti-Staphylococcus Aureus Phages over Clinical Strains

PHAXIAM Therapeutics Receives Compliance Notice from Nasdaq

New major risk - Financial position

PHAXIAM Therapeutics S.A. Announces Launch of New Preclinical Development

PHAXIAM Therapeutics S.A. to Report Q2, 2023 Results on Sep 21, 2023

New major risk - Shareholder dilution

ERYTECH Pharma S.A.(NasdaqCM:PHXM) dropped from NASDAQ Composite Index

ERYTECH Pharma S.A Announces Management Changes

Erytech Pharma S.A. Approves the Appointment of Robert Sebbag and Eric Leire as Directors

Akkadian Initiates Proceedings to Postpone the Vote on the Merger with Pherecydes

Mediobanca Banca di Credito Finanziario S.p.A. agreed to acquire an unknown minority stake in Anima Holding S.p.A. from Omnes Capital S.A.S., Auriga Partners, Ace Capital Partners, Go Capital SAS and Participations Besançon.

No longer forecast to breakeven

Insufficient new directors

ERYTECH Announces Receipt of Nasdaq Notice

ERYTECH Pharma S.A. to Report Q3, 2022 Results on Nov 21, 2022

ERYTECH Pharma to Stop Further Plans to Pursue A BLA Submission Seeking an Approval for Graspa® in Hypersensitive ALL

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Price target decreased to €5.80

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

ERYTECH Pharma Announces Publication of Positive Results from Eryaspase Phase 2 Trial

ERYTECH Pharma Expands Patent Portfolio for the Treatment of Rare Metabolic Diseases

ERYTECH Pharma Announces Presentation of Results of Two Clinical Trials of Eryaspase in Pancreatic Cancer at ASCO GI

No longer forecast to breakeven

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Analysts Expect Breakeven For ERYTECH Pharma S.A. (EPA:ERYP) Before Long

Price target decreased to €14.50

Consensus forecasts updated

Is ERYTECH Pharma (EPA:ERYP) Using Debt In A Risky Way?

Analysts update estimates

Earnings beat expectations, revenue disappoints

New 90-day low: €6.63

ERYTECH Pharma Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis

ERYTECH Pharma's (EPA:ERYP) Stock Price Has Reduced 60% In The Past Five Years

New 90-day high: €8.88

ERYTECH Pharma Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Completes Enrollment in TRYbeCA-1 Phase 3 Trial in Second-Line Pancreatic Cancer

ERYTECH Pharma (EPA:ERYP) Has Debt But No Earnings; Should You Worry?

New 90-day high: €8.02

New 90-day high: €6.50

Analysts update estimates

Revenue misses expectations

ERYTECH Pharma S.A. Announces That an Abstract Detailing Results from the NOPHO Sponsored Phase 2 Trial of Eryaspase in All Patients, Has Been Selected for Oral Presentation At the Upcoming 62nd American Society of Hematology (ASH) Annual Meeting

New 90-day low: €4.24

ERYTECH Pharma S.A. to Report Q2, 2021 Results on Sep 20, 2021

ERYTECH Pharma Appoints Stewart Craig as Chief Technical Officer and Member of the Executive Team

New 90-day low: €4.95

New 90-day low - €5.51

New 90-day low - €6.06

New 90-day low - €6.74

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령